Stanford scientists have developed fully human CD19-targeted CAR T cells designed to overcome the limitations of current CAR T cell therapies, particularly in treating low CD19 density blood cancers.
Stanford researchers have developed a novel, multi-specific chimeric antigen receptor (CAR) T-cell therapy designed to overcome the key challenges of treating solid tumors, including tumor heterogeneity, immune evasion, and CAR T-cell exhaustion.
Stanford researchers developed and patented a multiplexed immunohistochemistry method called multiplexed ion beam imaging (MIBI), which uses antibodies tagged with non-biological elemental isotopes (e.g. rare earth elements) and secondary ion mass spectroscopy.
Stanford scientists have discovered that a specific protein signaling pathway can promote regenerative wound healing by suppressing fibrosis-related mechanosignaling.
Stanford researchers in Prof. Michelle Monje's lab have developed a method for treating cognitive impairment (aka brain fog) caused by cancer immunotherapy.
Stanford researchers have developed a highly effective B7-H3 chimeric antigen receptor (CAR) for CAR-T cell therapy, designed to enhance binding and cytotoxicity against B7-H3 expressing solid tumors, offering a promising treatment for various cancers.
Researchers in Prof. Hongjie Dai's laboratory have developed a simple process to easily deposit plasmonic nanoscopic gold films on a variety of surfaces.
Osteopontin is a protein involved in the pathogenesis of cancer and chronic inflammatory diseases. Antibodies are a powerful tool that can be used to target this protein and regulate its pathway.
Researchers at Stanford have developed a novel strategy to enhance vaccine efficacy using mRNA lipid nanoparticles (LNPs) encoding immunostimulatory cytokines.
Hematopoietic stem and progenitor cells, collectively "HSPCs", are multipotent cells that can self-renew and differentiate into all types of blood cells, including cells of both myeloid and lymphoid lineage.
Stanford researchers have developed an innovative microfluidic platform, EV-Lev, for the isolation and sorting of extracellular vesicles (EVs) from human plasma.
Researchers at Stanford have developed a strategy to improve the efficacy of antibiotics by conjugating the antibiotic to a guanidinium-rich molecular transporter (GR-MoTr).
Stanford researchers have repurposed two existing drugs and created a combined nanoparticle formulation that provides both intraocular pressure management and neuroprotection for glaucoma therapy.
Stanford researchers in Prof. Corinne Beinat's lab have developed a novel radiotracer, [18F]hGTS13, for non-invasive imaging of system xc- activity, enabling the identification of ferroptosis-sensitive cancers and monitoring the efficacy of ferroptosis-inducing therapies.